VERA THERAPEUTICS INC
VERANASDAQTrading Snapshot
- Day Range
- $31.00 – $31.91
- 52-Week Range
- $23.05 – $56.05
- Volume (shares)
- 464,193.431
- Avg Volume (shares)
- —
- Shares Outstanding
- 72.1M
- Next Earnings
- 2026-11-05
Fundamentals Snapshot
- Annual Revenue
- —
- Last Q Revenue
- —
- P/E Ratio
- —
- P/S Ratio
- —
- EPS (TTM)
- $-5.86
- Dividend Yield
- —
- Dilution (1yr)
- +17.0%
VERA THERAPEUTICS INC
VERA
StockOtter · stockotter.spaceAbout VERA THERAPEUTICS INC
Vera Therapeutics, Inc. is a clinical-stage biotechnology company focused on the development and commercialization of treatments for significant immunological disorders, primarily within the United States. Their leading therapeutic candidate is atacicept, a fusion protein that patients self-administer as a subcutaneous injection. This drug is currently undergoing Phase IIb clinical trials to treat immunoglobulin A nephropathy. The company is also advancing MAU868, a monoclonal antibody in Phase 2 clinical development, designed to combat BK viremia infections. Founded in 2016 and based in Brisbane, California, the organization operated as Trucode Gene Repair, Inc. until it rebranded to Vera Therapeutics, Inc. in April 2020.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
Latest News & Updates
Vera Therapeutics' TRUTAKNA Delivers Strong Phase III IgA Nephropathy Results
Vera Therapeutics NASDAQ: VERA reported final efficacy results from its Phase III ORIGIN trial evaluating atacicept, marketed as TRUTAKNA, in adults with IgA nephropathy. The company presented the data at the American So
Vera Therapeutics, Inc. (VERA) Discusses Final Efficacy Results of ORIGIN Phase III Trial of Atacicept in IgA Nephropathy Transcript
Vera Therapeutics, Inc. (VERA) Discusses Final Efficacy Results of ORIGIN Phase III Trial of Atacicept in IgA Nephropathy Transcript
Vera Therapeutics Announces Positive ORIGIN 3 Final Efficacy Analysis of TRUTAKNA™ (atacicept-vymj) in IgA Nephropathy Presented at ASN Kidney Week 2026 and Published in the New England Journal of Medicine
TRUTAKNA, the first and only FDA-approved BAFF and APRIL inhibitor, achieved statistical significance in all prespecified endpoints, including eGFR change from baseline and annualized slope, and risk reduction in composi
Vera Therapeutics to Host ASN Kidney Week Investor Webcast and Third Quarter 2026 Financial Results Conference Webcast
Investor webcast at 4:30 p.m. ET on October 22 to discuss ORIGIN 3 final efficacy results for TRUTAKNA ™ (atacicept-vymj) featured in a late-breaking oral presentation during the opening plenary session of ASN Kidney Wee
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BRISBANE, Calif., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on September 29, 2026, the Compensation Committee of the Board of Directors (Compensation Committee) of Ver
Vera Therapeutics Announces ORIGIN 3 Final Efficacy Analysis of TRUTAKNA™ (atacicept-vymj) in IgA Nephropathy Will be A Featured Late-breaking Oral Presentation at the Opening Plenary Session of ASN Kidney Week 2026
ORIGIN 3 Final Efficacy Analysis of TRUTAKNA™ (atacicept-vymj) in IgAN Will be A Featured Late-breaking Oral Presentation at Opening Plenary of ASN 2026